A durable 4-1BB-based CD19 CAR-T cell for treatment of relapsed or refractory non-Hodgkin lymphoma.
Ying Z, He T, Jin S, Wang X, Zheng W, Lin N, Tu M, Xie Y, Ping L, Liu W, Deng L, Ding Y, Hu X, Bu B, Lu X, Song Y, Zhu J.
Ying Z, et al. Among authors: bu b.
Chin J Cancer Res. 2022 Feb 28;34(1):53-62. doi: 10.21147/j.issn.1000-9604.2022.01.05.
Chin J Cancer Res. 2022.
PMID: 35355931
Free PMC article.